The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Luspatercept reduces transfusion burden in β-thalassemia
Maria Domenica Cappellini, MD, of the University of Milan, Milan, Italy, discusses the results of the Phase III BELIEVE trial (NCT02604433), which is investigating luspatercept vs. a placebo in adults with β-thalassemia who require regular transfusions. She highlights how luspatercept significantly reduced transfusion burden and was generally well-tolerated. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
